Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs

Nucleic Acids Research

Volumn 43, Issue 18, 2015, Pages 8664-8672

  Osborn, Maire F ^a   Alterman, Julia F ^a   Nikan, Mehran ^a   Cao, Hong ^a   Didiot, Marie C ^a   Hassler, Matthew R ^a   Coles, Andrew H ^a   Khvorova, Anastasia ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANABENZ ACETATE; MESSENGER RNA; SMALL INTERFERING RNA; GUANABENZ; MOLECULAR LIBRARY;

ARTICLE; CELL TRANSPORT; CELLULAR PARAMETERS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG UPTAKE; ENDOSOMAL ESCAPE; ENHANCER REGION; GENE EXPRESSION; GENE SILENCING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC50; IN VITRO STUDY; INTERNALIZATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS; HELA CELL LINE; METABOLISM; MOLECULAR LIBRARY; RNA INTERFERENCE; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; GUANABENZ; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84978953634     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkv942     Document Type: Article

References (32)

1. Castanotto, D. and Rossi, J.J. (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature, 457, 426-433.
2. Davidson, B.L. and McCray, P.B. (2011) Current prospects for RNA interference-based therapies. Nat. Rev. Genet., 12, 329-340.
3. Zhou, J., Shum, K.-T., Burnett, J.C. and Rossi, J.J. (2013) Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals, 6, 85-107.
4. Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M. et al. (2013) Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol., 31, 638-646.
5. Gooding, M., Browne, L.P., Quinteiro, F.M. and Selwood, D.L. (2012) siRNA delivery: from lipids to cell-penetrating peptides and their mimics. Chem. Biol. Drug Des., 80, 787-809.
6. Varkouhi, A.K., Scholte, M., Storm, G. and Haisma, H.J. (2011) Endosomal escape pathways for delivery of biologicals. J. Control. Release, 151, 220-228.
7. Dahlman, J.E., Barnes, C., Khan, O.F., Thiriot, A., Jhunjunwala, S., Shaw, T.E., Xing, Y., Sager, H.B., Sahay, G., Speciner, L. et al. (2014) In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat. Nanotechnol., 9, 648-655.
8. Stalder, L., Heusermann, W., Sokol, L., Trojer, D., Wirz, J., Hean, J., Fritzsche, A., Aeschimann, F., Pfanzagl, V., Basselet, P. et al. (2013) The rough endoplasmatic reticulum is a central nucleation site of siRNA-mediated RNA silencing. EMBO J., 32, 1115-1127.
9. Nair, J.K., Willoughby, J.L.S., Chan, A., Charisse, K., Alam, R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel, A.V., Milstein, S. et al. (2014) Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc., 136, 16958-16961.
10. Byrne, M., Ford, G., Tzekov, R., Wang, Y., Rodgers, A., Cardia, J., Holton, K., Pandarinathan, L., Lapierre, J., Stanney, W. et al. (2013) Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye. J. Ocul. Pharmacol. Ther., 29, 855-864.
11. Wu, J., Huang, W. and He, Z. (2013) Dendrimers as carriers for siRNA delivery and gene silencing: a review. ScientificWorldJournal., 2013, 630654.
12. Kim, S.W., Kim, N.Y., Choi, Y.B., Park, S.H., Yang, J.M. and Shin, S. (2010) RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. J. Control. Release, 143, 335-343.
13. Crombez, L., Aldrian-Herrada, G., Konate, K., Nguyen, Q.N., McMaster, G.K., Brasseur, R., Heitz, F. and Divita, G. (2009) A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol. Ther., 17, 95-103.
14. Rozema, D.B., Lewis, D.L., Wakefield, D.H., Wong, S.C., Klein, J.J., Roesch, P.L., Bertin, S.L., Reppen, T.W., Chu, Q., Blokhin, A.V. et al. (2007) Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. U.S.A., 104, 12982-12987.
15. Wong, S.C., Klein, J.J., Hamilton, H.L., Chu, Q., Frey, C.L., Trubetskoy, V.S., Hegge, J., Wakefield, D., Rozema, D.B. and Lewis, D.L. (2012) Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acids Ther., 22, 380-390.
16. Gooding, M., Adigbli, D., Edith Chan, A.W., Melander, R.J., MacRobert, A.J. and Selwood, D.L. (2014) A bifurcated proteoglycan binding small molecule carrier for siRNA delivery. Chem. Biol. Drug Des., 84, 24-35.
17. Gooding, M., Tudzarova, S., Worthington, R.J., Kingsbury, S.R., Rebstock, A.-S., Dube, H., Simone, M.I., Visintin, C., Lagos, D., Quesada, J.-M.F. et al. (2012) Exploring the interaction between siRNA and the SMoC biomolecule transporters: implications for small molecule-mediated delivery of siRNA. Chem. Biol. Drug Des., 79, 9-21.
18. Ming, X., Carver, K., Fisher, M., Noel, R., Cintrat, J.-C., Gillet, D., Barbier, J., Cao, C., Bauman, J. and Juliano, R.L. (2013) The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides. Nucleic Acids Res., 41, 3673-3687.
19. Yang, B., Ming, X., Cao, C., Laing, B., Yuan, A., Porter, M.A., Hull-Ryde, E.A, Maddry, J., Suto, M., Janzen, W.P. et al. (2015) High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides. Nucleic Acids Res., 43, 1987-1996.
20. Baum, T. and Bruce, W. (1974) (2, 6-disubstituted benzylidene)amino guanidines and related compounds. US 3, 816, 531 A.
21. Kodama, J.K., Haynes, G.R. and Albert, J.R. (1976) Therapeutic Agents. US 3, 975, 533 A.
22. Moschos, S.A., Jones, S.W., Perry, M.M., Williams, A.E., Erjefalt, J.S., Turner, J.J., Barnes, P.J., Sproat, B.S., Gait, M.J. and Lindsay, M.A. (2007) Lung delivery studies using siRNA conjugated to TAT (48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug. Chem., 18, 1450-1459.
23. Ohara, K., Smietana, M. and Vasseur, J.-J. (2006) Characterization of specific noncovalent complexes between guanidinium derivatives and single-stranded DNA by MALDI. J. Am. Soc. Mass Spectrom., 17, 283-291.
24. Holmes, B., Brogden, R., Heel, R., Speight, T. and Avery, R. (1983) Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs, 26, 212-229.
25. Nguyen, P., Hammoud, H., Halliez, S., Pang, Y., Evrard, J., Blondel, M., Strasbourg, U. and De, F. (2014) Structure-activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost α2-adrenergic receptor agonistic activity. ACS Chem. Neurosci., 5, 1075-1082.
26. Tsaytler, P., Harding, H.P., Ron, D. and Bertolotti, A. (2002) Selective Inhibition of a Regulatory Subunit of a Protein Phosphatase 1 Restores Proteostasis. Science, 332, 91-94.
27. Jiang, H.-Q., Ren, M., Jiang, H.-Z., Wang, J., Zhang, J., Yin, X., Wang, S.-Y., Qi, Y., Wang, X.-D. and Feng, H.-L. (2015) Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neuroscience, 277, 132-138.
28. Wang, L., Popko, B., Tixier, E. and Roos, R.P. (2014) Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis. Neurobiol. Dis., 71, 317-324.
29. Tribouillard-Tanvier, D., Béringue, V., Desban, N., Gug, F., Bach, S., Voisset, C., Galons, H., Laude, H., Vilette, D. and Blondel, M. (2008) Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS One, 3, e1981.
30. Moreno, J.A., Radford, H., Peretti, D., Steinert, J.R., Verity, N., Martin, M.G., Halliday, M., Morgan, J., Dinsdale, D., Ortori, C.A. et al. (2012) Sustained translational repression by eIF2′-P mediates prion neurodegeneration. Nature, 485, 507-511.
31. Mahon, K.P., Love, K.T., Whitehead, K.A., Qin, J., Akinc, A., Leshchiner, E., Leshchiner, I., Langer, R. and Anderson, D.G. (2010) Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery. Bioconjug. Chem., 21, 1448-1454.
32. Whitehead, K.A., Dorkin, J.R., Vegas, A.J., Chang, P.H., Veiseh, O., Matthews, J., Fenton, O.S., Zhang, Y., Olejnik, K.T., Yesilyurt, V. et al. (2014) Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun., 5, 4277.